Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory

International Journal of Antimicrobial Agents
Neil WoodfordD M Livermore

Abstract

The emergence of carbapenem resistance in Enterobacteriaceae represents a major public health concern. We investigated ertapenem-resistant clinical isolates of Klebsiella spp. and Enterobacter spp. referred to the UK's national reference laboratory for antibiotic resistance. Minimum inhibitory concentrations (MICs) were determined and interpreted according to British Society for Antimicrobial Chemotherapy guidelines. Genes for carbapenemases and CTX-M extended-spectrum beta-lactamases (ESBLs) were sought by polymerase chain reaction, and imipenem hydrolysis was determined by spectrophotometry with crude extracts. From June 2004 to April 2006, 95 Klebsiella spp. and 76 Enterobacter spp. isolates resistant to ertapenem (MICs >2mg/L) were received, 40% of which (38 Klebsiella spp. and 30 Enterobacter spp.) were highly resistant to ertapenem (MICs >16mg/L). Imipenem and meropenem were active (geometric mean MICs <2mg/L) against most isolates with low-level ertapenem resistance but were less active against highly ertapenem-resistant isolates. Only one ertapenem-resistant isolate produced a defined carbapenemase, a Klebsiella pneumoniae with IMP-1 enzyme; one Enterobacter sp. also hydrolysed imipenem, but its carbapenemase remains to...Continue Reading

References

Jul 27, 2004·Antimicrobial Agents and Chemotherapy·George A JacobyNancy Chow
Jun 1, 2006·The Journal of Antimicrobial Chemotherapy·Nicola A C PotzUNKNOWN London & South East ESBL Project Group
Jul 15, 2006·The Journal of Antimicrobial Chemotherapy·J M Andrews, UNKNOWN BASC Working Party on Susceptibility Testing

❮ Previous
Next ❯

Citations

Jul 12, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F DonnarummaE Casalone
Jun 4, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J Cohen StuartM Leverstein-Van Hall
Dec 31, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sophia MüllerGiuseppe Valenza
Feb 22, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Eric GomezTom Chiang
Jul 30, 2008·The Journal of Antimicrobial Chemotherapy·Delphine GirlichPatrice Nordmann
Aug 12, 2008·The Journal of Antimicrobial Chemotherapy·David M LivermoreNeil Woodford
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·David M LivermoreUNKNOWN BSAC Working Parties on Resistance Surveillance
Oct 30, 2008·The Journal of Antimicrobial Chemotherapy·Christian G GiskeTimothy R Walsh
Jun 6, 2009·The Journal of Antimicrobial Chemotherapy·David M LivermoreMarina Warner
Aug 19, 2009·The Journal of Antimicrobial Chemotherapy·David M Livermore
Mar 9, 2012·The Journal of Antimicrobial Chemotherapy·L F MatasejeUNKNOWN Canadian Nosocomial Infection Surveillance Program
Sep 15, 2012·The Journal of Antimicrobial Chemotherapy·Marlen AdlerLinus Sandegren
Apr 6, 2013·The Journal of Antimicrobial Chemotherapy·Te-Din HuangUNKNOWN multicentre study group
Nov 3, 2010·Antimicrobial Agents and Chemotherapy·David M LivermoreNeil Woodford
Jun 22, 2007·Journal of Clinical Microbiology·K F AndersonJ B Patel
Apr 24, 2009·Journal of Clinical Microbiology·Fernando PasteranAlejandra Corso
Feb 14, 2009·Journal of Clinical Microbiology·Azita LeavittShiri Navon-Venezia
Dec 3, 2011·Journal of Clinical Microbiology·Fu-Chen YangJiunn-Jong Wu
Nov 28, 2008·Journal of Clinical Microbiology·Justin M ColeFrederick S Nolte
Jan 16, 2009·Journal of Clinical Microbiology·Shannon E McGettiganPaul H Edelstein
Jan 20, 2012·Journal of Clinical Microbiology·André BirgyEdouard Bingen
Aug 22, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Giuliana Lo CascioMaria M Lleo
Aug 3, 2014·Current Microbiology·Rita de Cássia Andrade MeloAna Catarina Souza Lopes
Jun 27, 2008·Journal of Perinatology : Official Journal of the California Perinatal Association·H Abdel-HadyR El-Kady
Jan 12, 2013·International Journal of Antimicrobial Agents·Stephen P HawserDavid L Paterson
Jul 6, 2010·International Journal of Antimicrobial Agents·James Cohen StuartUNKNOWN Dutch Working Party on the Detection of Highly Resistant Microorganisms
Apr 13, 2010·Enfermedades infecciosas y microbiología clínica·Rafael Cantón
Nov 10, 2009·Pathologie-biologie·A Carrër, P Nordmann
Apr 14, 2009·International Journal of Antimicrobial Agents·Mary Ashcroft, Michael Weinbren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.